2025 AHA/ACC 慢性冠心病临床绩效与质量措施
该文件由美国心脏病学会/美国心脏协会绩效措施联合委员会制定,针对慢性冠心病(CCD)提出包含10项绩效措施和3项质量措施的综合措施集,旨在将CCD管理对齐最新循证指南,涵盖烟草使用评估与戒烟干预、抗血小板治疗、血脂评估与LDL-C目标、高血压及左室功能减低的指南导向管理、心脏康复转诊和患者教育等主题。
要点
- 措施集涵盖烟草使用评估与循证戒烟干预。
- 包括抗血小板治疗、血脂评估与LDL-C目标。
- 强调高血压和左室功能减低的指南导向管理。
核心结论
- 制定综合措施集以推动慢性冠心病管理对齐最新循证指南。
研究设计与样本
- 由美国心脏病学会/美国心脏协会绩效措施联合委员会制定,包含10项绩效措施和3项质量措施。
关键数值与推荐
- 措施集包含10项绩效措施和3项质量措施。
- 措施主题包括烟草使用评估与循证戒烟干预、抗血小板治疗、血脂评估与LDL-C目标、高血压和左室功能减低的指南导向管理、心脏康复转诊和患者教育。
临床怎么用
- 临床可参照该措施集评估和改进慢性冠心病患者的循证照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
引用
- Williams, Levine, Kalra, et al. 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. J Am Coll Cardiol. 2025. PMID: 40310322. doi:10.1016/j.jacc.2025.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。